कनाडा - अंग्रेज़ी - Health Canada

sandoz canada incorporated - omeprazole - capsule (delayed release) - 20mg - omeprazole 20mg - proton-pump inhibitors

कनाडा - अंग्रेज़ी - Health Canada

laboratoire riva inc. - omeprazole (omeprazole magnesium) - tablet (delayed-release) - 20mg - omeprazole (omeprazole magnesium) 20mg - proton-pump inhibitors

कनाडा - अंग्रेज़ी - Health Canada

natco pharma (canada) inc - omeprazole (omeprazole magnesium) - tablet (delayed-release) - 20mg - omeprazole (omeprazole magnesium) 20mg - proton-pump inhibitors

कनाडा - अंग्रेज़ी - Health Canada

pharmapar inc - omeprazole (omeprazole magnesium) - tablet (delayed-release) - 20mg - omeprazole (omeprazole magnesium) 20mg - proton-pump inhibitors

कनाडा - अंग्रेज़ी - Health Canada

biomed pharma - omeprazole (omeprazole magnesium) - tablet (delayed-release) - 20mg - omeprazole (omeprazole magnesium) 20mg - proton-pump inhibitors

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

rebel distributors corp - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine 150 mg - nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. the consequences of continuous therapy with nizatidine for longer than 1 year are not known. nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gerd. nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

nucare pharmaceuticals, inc. - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 150 mg - ranitidine tablets usp are indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

cardinal health - ranitidine hydrochloride (unii: bk76465ihm) (ranitidine - unii:884kt10yb7) - ranitidine 150 mg

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

preferred pharmaceuticals, inc - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine 150 mg

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

state of florida doh central pharmacy - ranitidine (unii: 884kt10yb7) (ranitidine - unii:884kt10yb7) - ranitidine 150 mg - ranitidine tablets are indicated in: - short-term treatment of active duodenal ulcer. most patients heal within 4 weeks. studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. - maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. no placebo-controlled comparative studies have been carried out for periods of longer than 1 year. - the treatment of pathological hypersecretory conditions (e.g., zollinger-ellison syndrome and systemic mastocytosis). - short-term treatment of active, benign gastric ulcer. most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. - maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. placebo-controlled studies have been carried out for